Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 65, Issue 6, Pages (June 2014)

Similar presentations


Presentation on theme: "Volume 65, Issue 6, Pages (June 2014)"— Presentation transcript:

1 Volume 65, Issue 6, Pages 1191-1197 (June 2014)
Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival  Daniel C. Danila, Aseem Anand, Nikolaus Schultz, Glenn Heller, Mingliang Wan, Clifford C. Sung, Charles Dai, Raya Khanin, Martin Fleisher, Hans Lilja, Howard I. Scher  European Urology  Volume 65, Issue 6, Pages (June 2014) DOI: /j.eururo Copyright © 2013 European Association of Urology Terms and Conditions

2 Fig. 1 Selection of panel of prostate-specific genes highly expressed in prostate tissue and not expressed in peripheral blood mononuclear cells (PBMCs). The Tissue-specific Gene Expression and Regulation (TiGER) database [14], the Prostate Cancer Genomic Project (PCGP) database [15], and the Novartis Gene Expression database [16] (using BioGPS [17]) were queried for genes expressed in prostate tissue but not expressed in PBMCs or in more than two tissues other than prostate. PBMCs=peripheral blood mononuclear cells; RT-PCR=reverse transcription polymerase chain reaction. European Urology  , DOI: ( /j.eururo ) Copyright © 2013 European Association of Urology Terms and Conditions

3 Fig. 2 Prognostic value of detection of prostate-specific transcripts and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer. Kaplan-Meier estimate of survival, calculated from time of blood draw and based on (A) detection of two or more prostate-specific transcripts and (B) baseline CTC counts. European Urology  , DOI: ( /j.eururo ) Copyright © 2013 European Association of Urology Terms and Conditions

4 Fig. 3 Prognostic value of detection based on the combination of prostate-specific transcripts and circulating tumor cell enumeration in men with metastatic castration-resistant prostate cancer. The Kaplan-Meier estimate of survival, calculated from time of blood draw, based on whether zero, one, or two unfavorable risk factors were present. European Urology  , DOI: ( /j.eururo ) Copyright © 2013 European Association of Urology Terms and Conditions


Download ppt "Volume 65, Issue 6, Pages (June 2014)"

Similar presentations


Ads by Google